Výsledky vyhledávání

Differential effect of adjuvant taxane-based and taxane-free chemotherapy regimens on the CK-19 mRNA-positive circulating tumour cells in patients with early breast cancer

Autor: Sophia Agelaki, Stella Apostolaki, A. Xyrafas, Antonia Kalykaki, N. Xenidis, Konstantinos Kalbakis, M. Perraki, S. Kakolyris, N Vardakis, V. Georgoulias, D. Mavroudis

Publikováno v: British Journal of Cancer

Background: To determine the effect of adjuvant taxane-free and taxane-based chemotherapy regimens on the elimination of circulating tumour cells (CTCs) in patients with early breast cancer. Methods: The presence of CK-19 mRNA-positive CTCs in the pe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a31b15f0e8dd4d92c7d7db8ab08ede0d
http://europepmc.org/articles/PMC3593552

Zobrazit plný text záznamu

A triplet combination with irinotecan (CPT-11), oxaliplatin (LOHP), continuous infusion 5-fluorouracil and leucovorin (FOLFOXIRI) plus cetuximab as first-line treatment in KRAS wt, metastatic colorectal cancer: a pilot phase II trial

Autor: E Kabouraki, John Souglakos, D. Mavroudis, Z. Saridaki, L. Vamvakas, N Vardakis, Dora Hatzidaki, V. Georgoulias, Alexandra Voutsina, Konstantinos Kalbakis, Nikos Androulakis

Publikováno v: British Journal of Cancer

Background: We conducted an open-label, pilot phase II trial to evaluate the efficacy and safety of FOLFOXIRI plus cetuximab as first-line treatment of patients with metastatic colorectal cancer (mCRC). Methods: Thirty patients with KRAS wild-type mC

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::740c2faacefc7206f74d664196f62f3a
http://europepmc.org/articles/PMC3516691

Zobrazit plný text záznamu

Paclitaxel in combination with carboplatin as salvage treatment in patients with castration-resistant prostate cancer: a Hellenic oncology research group multicenter phase II study

Autor: Stylianos Giassas, V. Georgoulias, N. Vardakis, V. Bozionellou, Nikolaos Kentepozidis, A. Kotsakis, Elisavet Papadimitraki, A. Soultati, Antonia Kalykaki, N. Pantazopoulos

Publikováno v: Cancer Chemotherapy and Pharmacology. 70:161-168

To evaluate the efficacy and tolerance of biweekly paclitaxel and carboplatin combination in patients with castration-resistant prostate cancer.Patients were treated with paclitaxel at the dose of 135 mg/m(2) followed by carboplatin AUC 3 on day 1 ev

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::48a202cae99753c7a682f6388a70f38f
https://doi.org/10.1007/s00280-012-1896-9

Zobrazit plný text záznamu

A multicenter phase II trial of docetaxel plus gemcitabine as salvage treatment in anthracycline- and taxane-pretreated patients with metastatic breast cancer

Autor: N, Karachaliou, Ch, Kouroussis, P, Papakotoulas, K, Kalbakis, K, Tryfonidis, N, Vardakis, E, Poppis, V, Georgoulias, D, Mavroudis

Publikováno v: Cancer Chemotherapy and Pharmacology. 69:1345-1352

To evaluate the docetaxel-gemcitabine (DG) combination administered every 2 weeks as salvage therapy in anthracycline- and taxane-pretreated patients with metastatic breast cancer (MBC).Thirty women with MBC who had disease progression after chemothe

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::13d4e870d2feac70f5c8e6fc043ee0c0
https://doi.org/10.1007/s00280-012-1824-z

Zobrazit plný text záznamu

Modified CAPOX (Capecitabine plus Oxaliplatin) Regimen Every Two Weeks as Second-Line Treatment in Patients with Advanced Colorectal Cancer Previously Treated with Irinotecan-Based Frontline Therapy

Autor: S. Tsousis, Athanasios Athanasiadis, K. Amarantidis, John Souglakos, L. Vamvakas, Alexandros Ardavanis, Ioannis Varthalitis, Nikolaos Ziras, S. Kakolyris, V. Georgoulias, N. Vardakis, Aristidis Polyzos

Publikováno v: Oncology. 74:31-36

Background: To evaluate the efficacy and tolerance of capecitabine (CAP) given every other week and biweekly oxaliplatin (OX; modified CAPOX regimen) in patients with advanced colorectal cancer previously treated with irinote- can-based frontline che

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::6e08341abf77f097cc1abe10dcbc8df1
https://doi.org/10.1159/000138977

Zobrazit plný text záznamu

WITHDRAWN: Irinotecan plus Weekly 5-Fluorouracil and Leucovorin as Salvage Treatment for Patients with Metastatic Colorectal Cancer: A Phase II Trial

Autor: Sophia Agelaki, C. Kourousis, N. Androulakis, J. Souglakos, Stylianos Kakolyris, D. Mavroudis, N. Vardakis, V. Georgoulias, A. Pallis, Kostas Kalbakis

Publikováno v: Digestive Diseases. 25:100-105

A phase II study was conducted to evaluate the toxicity and efficacy of irinotecan/5-fluorouracil/leucovorin (CPT-11/5-FU/LV (AIO schedule)) as salvage treatment in patients with metastatic colorectal cancer.33 patients relapsing after oxaliplatin (L

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bcefd033fff7b5b7ea80ff93a613b2b1
https://doi.org/10.1159/000099177

Zobrazit plný text záznamu

A Dose-Escalation Study of Pegylated Liposomal Doxorubicin and Oxaliplatin in Patients with Advanced Solid Tumors

Autor: Sophia Agelaki, D. Mavroudis, Antonia Kalykaki, A. Kotsakis, Aristidis Polyzos, Ch. Kouroussis, L. Vamvakas, V. Georgoulias, N. Vardakis, Kostas Kalbakis, Nikos Androulakis

Publikováno v: Oncology. 71:190-196

Purpose: A phase I study was conducted to determine the maximum tolerated doses (MTDs) and dose-limiting toxicities (DLTs) of the pegylated liposomal doxorubicin (PLD) and oxaliplatin combination in patients with advanced solid tumors. Patients and M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::3a150407b3e0e6d9857b84a42f3f4df5
https://doi.org/10.1159/000106068

Zobrazit plný text záznamu

A Multicenter Phase II Study of the Combination of Irinotecan and Gemcitabine in Previously Treated Patients with Small-Cell Lung Cancer

Autor: Sophia Agelaki, Athanasios Athanasiadis, Charalambos Kouroussis, Maltezakis G, Charalambos Christophylakis, G. Milaki, Varthalitis J, N. Vardakis, Georgoulias, Kostas N. Syrigos, Georgia Pavlakou, J. Boukovinas

Publikováno v: Oncology. 66:192-196

Objective: To evaluate efficacy and toxicity of the combination of irinotecan and gemcitabine in pretreated patients having small-cell lung cancer. Patients andMethods: Thirty-one patients (median age 60 years, performance status 0–1 in 87% and 2 i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2bba6d30a2e123588e958c410cf1a9eb
https://doi.org/10.1159/000077994

Zobrazit plný text záznamu

Triplet Combination With Irinotecan Plus Oxaliplatin Plus Continuous-Infusion Fluorouracil and Leucovorin as First-Line Treatment in Metastatic Colorectal Cancer: A Multicenter Phase II Trial

Autor: Sophia Agelaki, John Souglakos, Dimitrios Tsetis, D. Mavroudis, S. Kakolyris, C. Kourousis, V. Georgoulias, George Samonis, N. Athanasiadis, N. Vardakis, Kostas Kalbakis, Nikos Androulakis

Publikováno v: Journal of Clinical Oncology. 20:2651-2657

PURPOSE: To evaluate the efficacy and tolerance of irinotecan (CPT-11) in combination with oxaliplatin (l-OHP) plus fluorouracil (5-FU)/leucovorin (LV) (de Gramont regimen) as first-line treatment of metastatic colorectal cancer (MCC). PATIENTS AND M

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::96b5225a0a902d66a93f4881ad3b69d4
https://doi.org/10.1200/jco.2002.08.015

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání